Clinical Trial Update: Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC [Phase 1]

View source ↗

Summary

Phase 1 study of Carotuximab (TRC105) in combination with Nivolumab in metastatic non-small cell lung carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Carotuximab (TRC105) (Carotuximab)
• nivolumab (nivolumab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2020-06-24